Residual Symptoms and the Quality of Life in Individuals Recovered From COVID-19 Infection: A Survey From Pakistan

• Sponsor: Aga Khan University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05148676
• Collaborator: (none)
• Enrollment: 331
• Location: 1
• Actual Duration (Months): 5.3
• Patients Per Site Per Month: 63

Study Details

Study Description

Brief Summary

There remains scarcity of literature regarding the patient's health status post-COVID-19 infection. This study analyzes the prevalence of residual symptoms and quality of life (QoL) after COVID-19.

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Pandemic; COVID-19 Respiratory Infection; COVID-19 Lower Respiratory Infection	Other: Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan

Detailed Description

An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.

A total of 331 COVID-19 survivors participated in our survey. Around 42.0% of the cohort reported within 1-3 months of diagnosis of COVID-19. The common residual symptoms were body aches (39.9%), low mood (32.6%), and cough (30.2%). Better physical QoL was associated with being male (adjusted beta: 3.328) and having no residual symptoms (6.955). However, suffering from nausea/vomiting during initial COVID-19 infection (-4.026), being admitted to the ICU during COVID-19 infection (-9.164), and suffering from residual body aches (-5.209) and low mood (-2.959) was associated with poorer QoL. Better mental QoL was associated with being asymptomatic during initial COVID-19 infection (6.149) and post-COVID (6.685), while experiencing low mood post-COVID was associated with poorer mental QoL (-8.253 [-10.914, -5.592]).

Despite presumed "recovery" from COVID-19, patients still face a wide range of residual symptoms months after initial infection, which contributes towards poorer QoL. Healthcare professionals must remain alert to the long-lasting effects of COVID-19 infection and aim to address them appropriately to improve patients' QoL.

Study Design

• Study Type: Observational
• Actual Enrollment: 331 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Residual Symptoms and the Quality of Life in Individuals Recovered From COVID-19 Infection: A Survey From Pakistan
• Actual Study Start Date: Nov 1, 2020
• Actual Primary Completion Date: Apr 1, 2021
• Actual Study Completion Date: Apr 10, 2021

Outcome Measures

Primary Outcome Measures

1. Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan [November 2020 to April 2021]

   The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• Tested negative for COVID-19 when enrolled in the study

• COVID-19 negative for at least 6 months

Exclusion Criteria:

• Still Positive for COVID-19 tested one week ago

• COVID-19 negative for less than 6 months

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Aga Khan University	Karachi	Sindh	Pakistan	7480 0

Sponsors and Collaborators

• Aga Khan University

Investigators

• Principal Investigator: Rubaid A Dhillon, MBBS, Aga Khan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Rubaid Azhar Dhillon, MBBS, Aga Khan University
• ClinicalTrials.gov Identifier: NCT05148676
• Other Study ID Numbers: 2021-5584-17843
• First Posted: Dec 8, 2021
• Last Update Posted: Dec 8, 2021
• Last Verified: Dec 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Rubaid Azhar Dhillon, MBBS, Aga Khan University: COVID-19; Residual Symptoms; Quality of Life
• Additional relevant MeSH terms: Infections; Communicable Diseases; COVID-19; Respiratory Tract Infections

Study Results

No Results Posted as of Dec 8, 2021